

## **A Pilot Randomized Trial of Oral Magnesium Supplementation on Supraventricular Arrhythmias**

Pamela L. Lutsey, Lin Y. Chen, Anne Eaton, Melanie Jaeb, Kyle D. Rudser, James D. Neaton, Alvaro Alonso

[PLL, MJ] Division of Epidemiology & Community Health, School of Public Health, University of Minnesota

[LYC] Cardiovascular Division, Department of Medicine, University of Minnesota, Minneapolis, MN.

[AE, KDR, JDN] Division of Biostatistics, School of Public Health, University of Minnesota

[AA] Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA

Corresponding author: Pamela Lutsey, PhD. Division of Epidemiology and Community Health, School of Public Health, University of Minnesota. 1300 S 2nd St, 300 West Bank Office Building, Minneapolis, MN 55454. Email: [lutsey@umn.edu](mailto:lutsey@umn.edu). Phone: +1 612-624-5812

# Abstract

**Background:** Magnesium is believed to have a physiologic role in cardiac contractility, and evidence from epidemiologic and clinical studies has suggested that low serum concentrations of magnesium may be associated with increased risk of atrial fibrillation (AF).

**Objective:** As part of the planning effort for a large randomized trial to prevent AF with magnesium supplementation, we conducted a 12-week pilot study to assess adherence to oral magnesium supplementation and matching placebo, estimate the effect on circulating magnesium concentrations, and evaluate the feasibility of using an ambulatory monitoring device (ZioPatch) for assessing premature atrial contractions (PACs), a predictor of AF.

**Design:** Double-blind randomized pilot clinical trial comparing supplementation with 400 mg magnesium oxide daily (versus placebo) over 12 weeks of follow-up. The ZioPatch was applied for 14 days at baseline and the end of follow-up. Adherence to the assigned treatment, and changes in PACs, serum magnesium concentration, glucose and blood pressure were assessed.

**Results:** A total of 59 participants, 73% women and average age 62 years, were randomized. 98% of participants completed follow-up. Those assigned to the magnesium supplement took 75% of tablets as compared to 83% for those in the placebo group. Change in magnesium concentrations was significantly greater for those given magnesium supplement compared to placebo (0.07; 95% confidence interval (CI): 0.03, 0.12 mEq/L;  $p = 0.002$ ). ZioPatch was worn for an average of 13.0 of the requested 14 days at baseline; at the end of follow-up, the average number of days of monitoring was 13.0 days for the magnesium supplement group and 12.7 days for the placebo group. For log PAC burden (episodes per hour), the average change from baseline was -0.05 (95% CI: -0.31, 0.20) for those randomized to magnesium supplement and 0.04 (95% CI: -0.24, 0.31) for those randomized to placebo ( $p=0.79$  for difference). Gastrointestinal problems were reported by 50% of participants in the magnesium supplement group and 7% in the placebo group. Only one person in the magnesium supplement group and none in the placebo group experienced adverse events which led to treatment discontinuation.

**Conclusions:** In this pilot randomized clinic trial, although gastrointestinal side effects to the magnesium supplement were common, adherence, measured by pill counts, was very good and, as a consequence, magnesium concentrations were greater for those randomly assigned to the magnesium supplement compared to placebo. Participant acceptance of the planned monitoring with ZioPatch was also very good. While the difference in the change in PACs was not significant, this pilot study was small, short-term, and did not include participants at high risk of AF. Thus, we could not reliably evaluate the effect of magnesium supplementation on PACs.

**Clinicaltrials.gov registration:** NCT02837328

## Background

Atrial fibrillation (AF) is a common cardiac arrhythmia characterized by irregular atrial electrical activity. In the US, more than 3 million individuals had AF in 2010, and this figure is expected to more than double by 2050.<sup>1-3</sup> Current AF treatments, including antiarrhythmic drugs and catheter ablation for rhythm restoration, and oral anticoagulation for the prevention of thromboembolism, have suboptimal efficacy and carry significant risks.<sup>4</sup> Limitations of the available therapeutic approaches highlight the need for primary prevention interventions.<sup>5,6</sup> As highlighted in a 2009 NHLBI report<sup>5</sup> and stressed in a more recent Heart Rhythm Society-sponsored whitepaper,<sup>6</sup> there is an urgent need to identify new and effective strategies for the primary prevention of AF.

Compelling evidence from numerous lines of inquiry suggests that low concentrations of serum magnesium may be causally associated with AF risk. First, magnesium supplementation is recommended as prophylaxis for the prevention of AF in patients undergoing cardiac surgery. A recent Cochrane systematic review and meta-analysis of randomized trials assessing the efficacy of magnesium supplementation for AF prevention in heart surgery reported an odds ratio of 0.55 (95%CI: 0.41, 0.73) for AF or supraventricular arrhythmia comparing the magnesium intervention to control.<sup>7</sup> Second, indirect evidence from three prospective epidemiologic studies provides some support for such intervention; each reported that individuals in the lowest versus highest quantile of serum magnesium were 35-50% more likely to develop incident AF, after multivariable adjustment.<sup>8-10</sup> Finally, additional evidence for an effect of magnesium on the risk of arrhythmias is provided by a study of dietary magnesium restriction in which 3 out of 14 women fed a low-magnesium diet developed AF, which resolved quickly after magnesium repletion.<sup>11</sup>

Whether magnesium supplementation could have a role in prevention of AF in the community has not been tested. Were magnesium supplementation shown to prevent AF and be safe over the long-term, it would be an ideal intervention for primary prevention as it is easy to implement and inexpensive.

As part of the planning effort for a large randomized trial to prevent AF with magnesium supplementation, we conducted a double-blind, placebo-controlled randomized clinical trial of oral magnesium supplementation to assess supplement adherence, side effects, effect on serum magnesium concentration, and feasibility of using an ambulatory monitoring device for identification of arrhythmias.

## Methods

### Study Participants

Participants 55 years of age or older were recruited using fliers, the University of Minnesota StudyFinder website, invitations to individuals enrolled in the ResearchMatch research volunteer database, and invitations to University of Minnesota School of Public Health employees. Exclusion criteria included a prior history of heart disease (coronary heart disease, heart failure, AF), stroke, known kidney disease; use of type I or III antiarrhythmic drugs or digoxin; current use of magnesium supplements; any prior history of allergy or intolerance to magnesium; lactose intolerance; prior history of inflammatory bowel disease or any severe gastrointestinal disorder.

Eligible participants attended a baseline visit where measurements were conducted and a Zio® XT Patch (ZioPatch; iRhythm Technologies, Inc., San Francisco, California) heart rhythm

monitor was applied by trained staff. After wearing the ZioPatch for 2 weeks, participants were randomized 1:1 to either 400 mg magnesium oxide or placebo using block randomization within two strata of age (younger than 65 and 65 and older). All participants provided written informed consent; the study protocol was approved by the University of Minnesota Institutional Review Board.

Following randomization, participants were mailed the study intervention, which they took for a total of 12 weeks. Ten weeks after beginning the study intervention, participants took part in a follow-up clinic visit, and a second ZioPatch was applied. Participants continued the study intervention until the second ZioPatch was removed (2 weeks after the follow-up clinic visit) (**Figure 1**).

### Study Intervention and Blinding

The University of Minnesota Institute for Therapeutics Discovery and Drug Development produced the active study intervention (400 mg magnesium oxide) and matched placebo (lactose) according to Good Manufacturing Practices. The University of Minnesota Investigational Drug Service managed bottling per the randomization scheme. Study participants and all study staff were blinded to the treatment given.

### Measurements

At the baseline and follow-up clinic visits, participants completed questionnaires and trained study staff conducted physiological measurements (i.e., anthropometry, blood pressure), phlebotomy, and applied the ZioPatch device. Treatment compliance was assessed by a pill count at the follow-up visit. At intervention days 21, 42 and 80 participants were also emailed unique links to online questionnaires, administered via REDCap,<sup>12</sup> which queried compliance and asked the following open-ended question about adverse effects: “Since starting the study, have you experienced anything out of the ordinary?” Participant blinding was also assessed on day 80, the last day of the study.

The ZioPatch was used to identify premature atrial contractions (PACs). PACs are supraventricular arrhythmias associated with the future risk of AF<sup>13-15</sup> and are considered an intermediate phenotype of the arrhythmia, reflecting the underlying cardiac substrate that facilitates the development of AF.<sup>16</sup> Participants were asked to wear the ZioPatches for 2 weeks after each clinic visit. Information obtained from the ZioPatch devices was processed by the ZEUS algorithm, a comprehensive system that analyzes electrocardiographic data received from the device.<sup>17</sup> We counted as PACs isolated supraventricular ectopic beats, supraventricular ectopic couplet total count, and supraventricular ectopic triplet total count. Total PACs were then divided by number of hours the ZioPatch recorded analyzable data, which yielded PACs per hour.

Participants were asked to fast for 8 hours prior to blood draws. Serum magnesium and glucose were measured using the Roche Cobas 6000 at the University of Minnesota Advanced Research and Diagnostic Laboratory. Blood pressure was measured with the participant sitting, after a 5 minute rest, with a random zero sphygmomanometer (Omron Digital Blood Pressure Monitor HEM-907XL). Three measurements were taken; all three measurements were averaged for use in analyses. Height and weight were measured with participants in light clothing, and shoes removed. Height was measured with a research stadiometer and weight with a scale.

### Statistical Analysis

The goal of the pilot study was to assess adherence to the Mg supplement, and feasibility of using the ZioPatch and collect preliminary data on PACs, a predictor of AF. Sample size was determined to detect a difference in the change in PACs (follow-up minus baseline) between treatment groups of 0.79 standard deviation units with 80% power and 5% type I error (2-sided), assuming 5 participants would not complete follow-up.

All analyses were intent-to-treat. Descriptive statistics are provided according to treatment assignment for baseline characteristics, adherence, Mg concentrations and other outcomes. Linear regression was used to evaluate whether change in outcomes differed according to treatment assignment, adjusting for the randomization stratification factor (age  $\geq 65$  vs  $< 65$ ) and baseline value of the outcome with robust variance estimates for confidence intervals and P-values. Post-hoc sensitivity analyses further adjusted for sex. As PAC burden is highly skewed, we pre-specified using log PAC burden for analysis and reported the ratio of geometric means. Pre-specified subgroup analyses were also performed, stratified by baseline magnesium concentration ( $<$  vs.  $\geq$  median). A 2-sided p-value of  $< 0.05$  was used to indicate statistical significance. Analyses were conducted using R<sup>18</sup> version 3.4.0 (R Foundation, Vienna, Austria).

## Results

### Study Participants

Between March and June 2017, 59 participants were randomized, 29 to Mg supplement and 30 to matching placebo. Participant characteristics were generally similar by treatment group, with the notable exception of sex; 86.2% of participants in the treatment group were women while in the placebo group 60.0% were female (**Table 1**). The mean age of participants was  $61.5 \pm 5.2$  years. Baseline serum magnesium was  $1.74 \pm 0.11$  mEq/L in participants assigned magnesium supplements and  $1.71 \pm 0.10$  in those assigned placebo; 6.9% had magnesium concentrations below the threshold for clinical deficiency ( $< 1.5$  mEq/L) while 37.9% had concentrations below the threshold for subclinical deficiency ( $< 1.7$  mEq/L).

Log PAC burden (episodes per hour) at baseline was  $1.14 \pm 1.40$  in the treatment group and  $0.95 \pm 1.53$  in the placebo group. At baseline, average ZioPatch analyzable time in the intervention and placebo groups were  $13.1 \pm 1.7$  and  $12.9 \pm 2.6$  days, respectively, with 93.1% assigned to magnesium and 90.0% assigned to placebo wearing  $\geq 12$  days.

### Follow-up

A total of 2 participants, both in the intervention group, were missing ZioPatch information at follow-up; 1 participant dropped out of the study and 1 due to a device malfunction (Figure 1).

### Adherence and Mg Concentrations

Based on pill count, participants in the magnesium group took  $75.1\% \pm 17.8\%$  of tablets, whereas those in the placebo group took  $83.4\% \pm 5.9\%$ . Self-reported information about the percent missing pills, and reasons for missing pills, is provided in **Table 2**.

Over the 12 week follow-up period those assigned magnesium supplementation had a significant increase in serum magnesium concentration as compared to placebo (0.07 mEq/L; 95% CI: 0.03, 0.12;  $p=0.002$ ) (**Table 3**). In subgroup analyses change in magnesium concentration did not vary by baseline magnesium concentration (**Table 4**; interaction 0.24). Specifically, among participants who at baseline were below the median serum magnesium

concentration (i.e. 1.74 mEq/L), the effect of magnesium versus placebo on change in serum magnesium concentration was 0.05 (95% CI: 0.00, 0.10) whereas among those at or above the median at baseline the effect was 0.12 (95% CI: 0.04, 0.20).

### Effect of magnesium supplementation on trial outcomes

**Table 3** presents study outcome values at baseline and follow-up, as well as age- and baseline value-adjusted differences in change according to intervention assignment. Spaghetti plots depicting individual change over the intervention period are provided in **Figure 2**. At follow-up, average wear times were similar to baseline, with  $13.0 \pm 1.8$  days for the intervention group,  $12.7 \pm 2.3$  days for the placebo group, and 92.6% assigned to magnesium and 73.3% assigned to placebo wearing  $\geq 12$  days. For the primary outcome, log PAC burden (episodes per hour), change over the intervention period was -0.05 (95% confidence interval (CI): -0.31, 0.20) for those randomized to magnesium supplement and 0.04 (95% CI: -0.24, 0.31) for those randomized to placebo. In multivariable-adjusted models there was no evidence of an intervention effect; the ratio of geometric means was 0.96 (95% CI: 0.70, 1.31), p-value = 0.79. Similarly, in subgroup analyses the effect did not differ according to baseline magnesium concentration above versus below the median (**Table 4**; p-interaction = 0.85).

Magnesium supplementation was not significantly associated with change in serum glucose [2.4 (95% CI: -3.0, 7.7) mg/dl; p = 0.39]. The lack of association remained in sensitivity analyses excluding one participant with extremely high baseline glucose [2.8 (95% CI: -0.9, 6.4) mg/dl] and one participant who reported changing his/her diabetes medication status during follow-up [2.0 (95% CI: -3.6, 7.5) mg/dl]. The intervention was also not significantly associated with change in systolic or diastolic blood pressure overall [2.9 (95% CI: -1.4, 7.2) mmHg and -0.5 (95% CI: -3.5, 2.5) mmHg, respectively], or after excluding two participants who changed their blood pressure medication status between the baseline and follow-up visits (data not shown).

In post-hoc analyses where we additionally adjusted for sex, results were similar (data not shown). Also, no meaningful patterns emerged in additional subgroup analyses by age category and sex (data not shown).

### Safety and tolerability of the intervention

When asked an open-ended question about adverse events, the most commonly reported responses related to gastrointestinal (GI) symptoms. Of the intervention group, 32% commented on GI changes at intervention day 21, 30% at day 42, and 33% at day 80. In the placebo group 7% commented on GI changes at day 21, 4% at day 42, and 0% at day 80. When considering unique individuals, 50% assigned to magnesium and 7% assigned to placebo commented on GI changes at any point in the study. Specific GI comments, by study participation day, are provided in **Supplemental Table 1**.

One person in the intervention group experienced side effects which led the participant to discontinue blinded study treatment.

At the end of the study, when asked what group they were assigned to, among those assigned to the active treatment, 15% guessed magnesium supplements, 14.3% placebo, and 35.7% reported not knowing (15 did not respond). Of those assigned to placebo, 4.3% guessed magnesium supplements, 26.1% placebo, and 69.6% reported not knowing (7 did not respond).

## **Discussion**



In this pilot trial of 59 relatively healthy adults aged 55 and older, supplementation with 400 mg magnesium daily over 12 weeks was safe and well-tolerated, and led to a change of 0.07 mEq/L in serum magnesium, which is substantial enough in magnitude that in a larger sample size may translate to health outcomes. The intervention was not associated with change in PACs, but estimates of association had wide confidence intervals and the study was not powered to identify important differences. Likewise, there was no association between supplemental magnesium and change in glucose, systolic blood pressure, or diastolic blood pressure.

The mechanisms through which magnesium supplementation could reduce the risk of supraventricular arrhythmias and AF are not fully understood. However, magnesium is known to play a direct role in cardiac contractility.<sup>19</sup> Small studies in healthy individuals and in patients with cardiac disease have found that intravenous magnesium administration prolongs sinoatrial, intra-atrial, and atrioventricular node conduction, and the atrial refractory period, which in turn may contribute to prevent onset of AF.<sup>20-22</sup> Also, randomization to 148 mg oral magnesium (and 296 mg potassium) intake (vs. placebo) had antiarrhythmic effects among 232 patients with frequent ventricular arrhythmias.<sup>23</sup>

Blood pressure and diabetes are also established risk factors for AF,<sup>24,25</sup> through which magnesium may lower AF risk. In the present pilot trial changes in blood pressure and serum glucose did not differ significantly between those given magnesium supplementation and those given placebo. This is in contrast to the existing literature; however, our study was small and confidence intervals around the treatment differences were wide. Meta-analyses of RCTs have consistently demonstrated that magnesium supplementation lowers blood pressure in a dose-dependent manner.<sup>26-28</sup> In the most recent meta-analysis, a median dose of 368 mg/d for a median duration of 3 months significantly reduced systolic BP by 2.0 mm Hg (95% CI: 0.4, 3.6) and diastolic BP by 1.8 mm Hg (95% CI: 0.7, 2.8).<sup>28</sup> Based partly on this evidence, in November 2016 a petition was filed with the Food and Drug Administration (FDA) for a qualified health claim for magnesium and reduced risk of high blood pressure (FDA-2016-Q-3770). A comparable meta-analysis of RCTs, including a total of 370 patients with type 2 diabetes (median intervention duration of 12 weeks, median oral magnesium dose of 360 mg/day), found that magnesium supplementation reduced levels of fasting blood glucose (-10.1 mg/dl, 95%CI -19.8, -0.2).<sup>29</sup> These meta-analyses suggest that magnesium is causally related to hypertension and abnormal glucose homeostasis. However, their interpretation is complicated by the fact that the individual studies included in the meta-analyses were highly heterogeneous in terms of magnesium formulation and dosage, and participant characteristics.

In terms of serum magnesium, the intervention of 400 mg magnesium oxide daily was associated with a serum increase of 0.07 mEq/L. This finding is concordant with results from a meta-analysis of the effect of magnesium supplementation dosage on serum magnesium response. In the meta-analysis the median dose was 360 mg/day, intervention length 12 weeks and response 0.08 mEq/L.<sup>30</sup> In the meta-analysis there was evidence of an inverse relationship between baseline magnesium concentration and responsiveness to supplementation. A similar phenomenon was not observed in the present trial, however in our sample baseline magnesium concentrations were quite high and power was exceedingly low for subgroup comparisons.

Results from this study provide additional evidence about the compliance with magnesium supplementation at the dosage of 400 mg magnesium daily, and also safety and tolerability. Among the participants randomized to magnesium only 1 of 29 participants (3.5%) ceased the intervention due to side-effects. Compliance in this study was good, at 75% in the

intervention group and 83% in the placebo group, according to pill counts. The low drop-out rate and high compliance provides support for the tolerability of this dosage. However, the fact that 50% in the intervention group commented on GI changes at some point in follow-up should not be dismissed. Unfortunately, given the way side-effects were assessed, it is not possible to quantify the severity of GI complaints. Notably, several individuals only commented about GI changes the first few days after taking the study treatment.

The primary limitation of this study is the small size. An additional consideration is that baseline serum concentrations of the trial participants were quite high; it is unclear how serum magnesium would have changed in a context of low magnesium, and how that may translate to change in other physiologic outcomes. Lastly, we assessed tolerability with a simple open-ended question, not a checklist of specific signs and symptoms graded for severity according to a standard toxicity table.

In sum, this small pilot double-blinded randomized controlled trial of supplementation with 400 mg magnesium daily provides evidence to support the safety and tolerability of this intervention, and also for adherence to the ZioPatch heart rhythm monitoring device. Despite our study population being largely magnesium replete, a change in serum magnesium was observed. Magnesium supplementation was not associated with change in PACs, glucose or blood pressure, however this small pilot study was short-term and not powered to identify small to moderate clinically relevant differences. Results of this pilot study will guide the design of a large trial to evaluate the effect of supplemental magnesium on arrhythmias.

## Funding

This manuscript was supported by McKnight Land-Grant Professorship funds (Lutsey), American Heart Association grant 16EIA26410001 (Alonso) and T32HL129956 (Eaton).



# References

1. Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults. National implications for rhythm management and stroke prevention: the Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study. *JAMA*. 2001;285:2370-2375.
2. Miyasaka Y, Barnes ME, Gersh BJ, et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. *Circulation*. 2006;114(2):119-125.
3. Mozaffarian D, Benjamin EJ, Go AS, et al. Heart disease and stroke statistics-2015 update: a report from the American Heart Association. *Circulation*. 2015;131(4):e29-e322.
4. January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. *Circulation*. 2014;130(23):e199-e267.
5. Benjamin EJ, Chen P-S, Bild DE, et al. Prevention of atrial fibrillation: report from an NHLBI workshop. *Circulation*. 2009;119:606-618.
6. Van Wagoner DR, Piccini JP, Albert CM, et al. Progress toward the prevention and treatment of atrial fibrillation: A summary of the Heart Rhythm Society Research Forum on the Treatment and Prevention of Atrial Fibrillation, Washington, DC, December 9–10, 2013. *Heart Rhythm*. 2015;12(1):e5-e29.
7. Arsenault KA, Yusuf AM, Crystal E, et al. Interventions for preventing post-operative atrial fibrillation in patients undergoing heart surgery. *Cochrane Database Syst Rev*. 2013(1):CD003611.
8. Khan AM, Lubitz SA, Sullivan LM, et al. Low serum magnesium and the development of atrial fibrillation in the community: the Framingham Heart Study. *Circulation*. 2013;127(1):33-38.
9. Misialek JR, Lopez FL, Lutsey PL, et al. Serum and dietary magnesium and incidence of atrial fibrillation in whites and in African Americans--Atherosclerosis Risk in Communities (ARIC) Study. *Circ J*. 2013;77(2):323-329.
10. Markovits N, Kurnik D, Halkin H, et al. Database evaluation of the association between serum magnesium levels and the risk of atrial fibrillation in the community. *Int J Cardiol*. 2016;205:142-146.
11. Nielsen FH, Milne DB, Klevay LM, Gallagher S, Johnson L. Dietary magnesium deficiency induces heart rhythm changes, impairs glucose tolerance, and decreases serum cholesterol in post menopausal women. *J Am Coll Nutr*. 2007;26(2):121-132.
12. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research Electronic Data Capture (REDCap) - A metadata-driven methodology and workflow process for providing translational research informatics support. *Journal of biomedical informatics*. 2009;42(2):377-381.
13. Dewland TA, Vittinghoff E, Mandyam MC, et al. Atrial Ectopy as a Predictor of Incident Atrial Fibrillation A Cohort Study. *Annals of Internal Medicine*. 2013;159(11):721-+.
14. Chong BH, Pong V, Lam KF, et al. Frequent premature atrial complexes predict new occurrence of atrial fibrillation and adverse cardiovascular events. *Europace*. 2012;14(7):942-947.
15. Van Wagoner DR, Piccini JP, Albert CM, et al. Progress toward the prevention and treatment of atrial fibrillation: A summary of the Heart Rhythm Society Research Forum on the Treatment and Prevention of Atrial Fibrillation, Washington, DC, December 9-10, 2013. *Heart Rhythm*. 2015;12(1):e5-e29.
16. Conen D, Adam M, Roche F, et al. Premature atrial contractions in the general population: frequency and risk factors. *Circulation*. 2012;126(19):2302-2308.
17. Turakhia MP, Hoang DD, Zimetbaum P, et al. Diagnostic utility of a novel leadless arrhythmia monitoring device. *Am J Cardiol*. 2013;112(4):520-524.

18. R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. . 2016; URL <https://www.R-project.org/>.
19. Byrd-Bredbenner C, Moe G, Beshgetoor D, Berning J. *Wardlaw's perspectives in nutrition*. 9th ed. New York: McGraw-Hill; 2013.
20. Christiansen EH, Frost L, Andreasen F, Mortensen P, Thomsen PE, Pedersen AK. Dose-related cardiac electrophysiological effects of intravenous magnesium. A double-blind placebo-controlled dose-response study in patients with paroxysmal supraventricular tachycardia. *Europace*. 2000;2(4):320-326.
21. Rasmussen HS, Thomsen PE. The electrophysiological effects of intravenous magnesium on human sinus node, atrioventricular node, atrium, and ventricle. *Clin Cardiol*. 1989;12(2):85-90.
22. Kulick DL, Hong R, Ryzen E, et al. Electrophysiologic effects of intravenous magnesium in patients with normal conduction systems and no clinical evidence of significant cardiac disease. *American heart journal*. 1988;115(2):367-373.
23. Zehender M, Meinertz T, Faber T, et al. Antiarrhythmic Effects of Increasing the Daily Intake of Magnesium and Potassium in Patients With Frequent Ventricular Arrhythmias fn1fn1This study was supported by Trommsdorff GmbH and Company, Alsdorf, Germany and Hexal AG, Holzkirchen, Germany. *Journal of the American College of Cardiology*. 1997;29(5):1028-1034.
24. Huxley RR, Fillion KB, Konety S, Alonso A. Meta-analysis of cohort and case-control studies of type 2 diabetes mellitus and risk of atrial fibrillation. *Am J Cardiol*. 2011;108(1):56-62.
25. Roetker NS, Chen LY, Heckbert SR, et al. Relation of systolic, diastolic, and pulse pressure and aortic distensibility with atrial fibrillation (from the Multi-Ethnic Study of Atherosclerosis). *Am J Cardiol*. 2014;114(4):587-592.
26. Jee SH, Miller ER, 3rd, Guallar E, Singh VK, Appel LJ, Klag MJ. The effect of magnesium supplementation on blood pressure: a meta-analysis of randomized clinical trials. *Am J Hypertens*. 2002;15(8):691-696.
27. Kass L, Weekes J, Carpenter L. Effect of magnesium supplementation on blood pressure: a meta-analysis. *Eur J Clin Nutr*. 2012;66:411-418.
28. Zhang X, Li Y, Del Gobbo LC, et al. Effects of Magnesium Supplementation on Blood Pressure: A Meta-Analysis of Randomized Double-Blind Placebo-Controlled Trials. *Hypertension*. 2016;68(2):324-333.
29. Song Y, He K, Levitan EB, Manson JE, Liu S. Effects of oral magnesium supplementation on glycaemic control in type 2 diabetes: a meta-analysis of randomized double-blind controlled trials. *Diabetic Medicine*. 2006;23:1050-1056.
30. Zhang X, Del Gobbo LC, Hruby A, et al. The circulating concentration and 24-h urine excretion of magnesium dose- and time-dependently respond to oral magnesium supplementation in a meta-analysis of randomized controlled trials. *J Nutr*. 2016;146(3):595-602.

**Table 1:** Baseline participant characteristics\* overall and stratified by intervention status.

	Overall	Magnesium (400 mg daily)	Placebo
<i>N</i>	59	29	30
<u><i>Demographics</i></u>			
Age, years	61.5 ± 5.2	61.3 ± 5.3	61.6 ± 5.2
Age category			
≥ 65 years	14 (23.7)	6 (20.7)	8 (26.7)
< 65 years	45 (76.3)	23 (79.3)	22 (73.3)
Sex			
Female	43 (72.9)	25 (86.2)	18 (60.0)
Male	16 (27.1)	4 (13.8)	12 (40)
Race			
White	56 (94.9)	27 (93.1)	29 (96.7)
Nonwhite	3 (5.1)	2 (6.9)	1 (3.3)
Educational attainment			
High school graduate or GED	1 (1.7)	0 (0)	1 (3.3)
Some college	10 (16.9)	6 (20.7)	4 (13.3)
College graduate	26 (44.1)	10 (34.5)	16 (53.3)
Graduate school or professional school	22 (37.3)	13 (44.8)	9 (30)
<u><i>Physiologic characteristics</i></u>			
BMI, kg/m <sup>2</sup>	27.9 ± 4.64	27.7 ± 4.9	28.0 ± 4.5
Serum magnesium, mEq/L	1.72 ± 0.11	1.74 ± 0.12	1.71 ± 0.10
Systolic blood pressure, mmHg	119 ± 16	119 ± 14	119 ± 18
Diastolic blood pressure, mmHg	71 ± 9	72 ± 9	71 ± 10
Antihypertensive medication	14 (24)	9 (31)	5 (17)
Serum glucose, mg/dL	98.9 ± 29.9	94.2 ± 10.6	103.2 ± 40.2
Sensitivity analysis**	95.2 ± 11.1	94.2 ± 10.6	96.2 ± 11.6
Glucose lowering medication	2 (3.4)	0 (0)	2 (6.7)
PAC burden, episodes/hour	13.9 ± 56	8.1 ± 14	19.5 ± 78
[25 <sup>th</sup> , 75 <sup>th</sup> percentiles]	[1.07, 6.01]	[1.18, 6.99]	[1.03, 3.69]
Log PAC burden, log(episodes/hour)	1.04 ± 1.46	1.14 ± 1.40	0.95 ± 1.53

\*mean ± SD or n (%)

\*\*Omission of one participant with a baseline glucose value of 307 mg/dL

**Table 2:** Self-reported compliance.

Compliance	% reporting missing pills in:			Reason for missing pills, N			
	Last 3 days	Last week	Last 2 weeks	Forgot	Too busy	Makes me sick	Other
Intervention Day 21							
Mg	8%	12%	20%	2	0	2	1
Placebo	0%	7%	24%	7	1	0	0
Intervention Day 42							
Mg	22%	33%	39%	5	0	5	1
Placebo	15%	22%	31%	6	2	0	2
Intervention Day 80							
Mg	14%	27%	40%	5	0	1	0
Placebo	12%	23%	28%	6	1	0	1

**Table 3:** Change in PACs, and secondary endpoints (i.e. SBP, DBP and serum glucose, Mg) according to treatment group

	Magnesium (400 mg daily) Mean (SD)	Placebo Mean (SD)	Intervention effect coefficient* (95% CI)	p-value
Primary outcome (episodes/hr)				
Log PAC burden			0.96 (0.70, 1.31)**	0.79
Baseline	1.14 (1.4)	0.95 (1.53)		
Follow-up <sup>†</sup>	1.06 (1.46)	0.98 (1.58)		
Change	-0.05 (0.65)	0.04 (0.74)		
PAC burden			0.49 (-2.5, 3.48)	
Baseline	8.1 ± 14	19.5 ± 78		
Follow-up <sup>†</sup>	7.7 ± 12	14.2 ± 47		
Change	-0.5 ± 7	-5.4 ± 32		
Secondary outcomes				
Serum magnesium, mEq/L			0.07 (0.03, 0.12)	0.002
Baseline	1.74 (0.12)	1.71 (0.1)		
Follow-up <sup>‡</sup>	1.8 (0.13)	1.71 (0.11)		
Change	0.07 (0.09)	0 (0.1)		
Serum glucose, mg/dL				
Baseline	94.2 (10.6)	103.2 (40.2)	2.4 (-3.0, 7.7)	0.39
Follow-up <sup>‡</sup>	96.3 (12.2)	96.2 (13.7)		
Change	1.8 (7.5)	-7.1 (32.8)		
Serum glucose <sup>¥</sup> , mg/dL				
Baseline	94.2 (10.6)	96.2 (11.6)	2.8 (-0.9, 6.4)	0.14
Follow-up <sup>‡</sup>	96.3 (12.2)	95 (12.4)		
Change	1.75 (7.5)	-1.21 (6.7)		
Systolic blood pressure, mmHg			2.9 (-1.8, 7.2)	0.18

Baseline	119 (14)	119 (18)		
Follow-up <sup>‡</sup>	118 (14)	115 (14)		
Change	-1 (10)	-4 (10)		
Diastolic blood pressure, mmHg			-0.5 (-3.5, 2.5)	0.74
Baseline	71.8 (8.7)	70.6 (10.3)		
Follow-up <sup>‡</sup>	71.0 (8.8)	70.8 (8.7)		
Change	-0.5 (7.1)	0.2 (6.1)		

\*Adjusted for age ( $\geq 65$  or  $< 65$ ), and baseline concentration (e.g. when change in glucose is the outcome, models were adjusted for baseline glucose). The numbers of observations included in linear models are 57, 57, 54, 54, 53, 58 and 58 respectively for the outcomes log PAC burden, PAC burden, serum magnesium, serum glucose, serum glucose excluding outlier, systolic blood pressure and diastolic blood pressure, respectively.

\*\* Presented as a ratio of geometric means, i.e.  $\exp(\text{coefficient})$

<sup>†</sup>ZioPatch was worn for a 2-week period, from the follow-up clinic visit (intervention week 10) through the end of the study (intervention week 12)

<sup>‡</sup>Follow-up information obtained at clinic visit (intervention week 10)

<sup>¥</sup>Outlier removed.



**Table 4:** Change in PACs, and secondary endpoints (i.e. SBP, DBP and serum glucose, Mg) according to treatment group, stratified by baseline serum Mg concentration.

Baseline serum Mg concentration					
	< median		≥ median		P-interaction
Primary outcome	Intervention effect coefficient* (95% CI)	p-value	Intervention effect coefficient* (95% CI)	p-value	
Log PAC burden	0.87 (0.51, 1.48)**	0.62	0.93 (0.63, 1.37)**	0.70	0.85
Serum magnesium, mEq/L	0.05 (0, 0.10)	0.04	0.12 (0.04,0.20)	0.004	0.24
Serum glucose, mg/dL	-4.7(-13.3, 4.0)	0.29	6.0 (2.0, 10.0)	0.03	0.06
Serum glucose, mg/dL <sup>‡</sup>	-3.2 (-9.0, 2.6)	0.28	6.0 (2.0, 10.0)	0.03	0.01
Systolic blood pressure, mmHg	4.8 (1.0, 8.5)	0.01	3.8 (-2.5, 10.2)	0.24	0.96
Diastolic blood pressure, mmHg	5.5(0.6, 10.4)	0.03	2.4 (-5.6, 0.8)	0.14	0.009

\*Adjusted for age (≥65 or <65) and baseline concentration (e.g. when change in glucose is the outcome, models were adjusted for baseline glucose).


<sup>‡</sup>Outlier removed.

\*\* Ratio of geometric means


**Figure 1:**


Footnote: \*Due to missing data on individual items, the total numbers of observations included in linear models are 57, 57, 54, 54, 58 and 58 respectively for the outcomes log PAC burden, PAC burden, serum magnesium, serum glucose, systolic blood pressure and diastolic blood pressure, respectively.

## CONSORT 2010 Flow Diagram



**Figure 2:** Spaghetti plots for change in log PAC burden, change in serum Mg, serum glucose\* and SBP.





\*One participant had a baseline glucose concentration of 307 mg/dL. The baseline value for this participant is outside the frame.